10-11 June 2021
Summit Co-Chairs
Faculty
Learning Objectives
Accreditation
The programme of this event will be accredited with ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further information please refer to ESMO-MORA Recertification Process & Requirements.
PROGRAMME
Thursday, June 10th 2021 (Central European Summer Time)
09:50-10:00 – Welcome & Introduction.
Welcome from RUSSCO and ESMO
Karin Jordan, ESMO
Alexey Tryakin, RUSSCO
SESSION 1. Head and Neck Carcinoma
Chairs:
Jean-Pascal Machiels, BE
Ilya Romanov, RU
10:00-10:20 – Advances of 2020-2021 in the locoregional treatment
Jean-Pascal Machiels, BE
10:20-10:25 – Q&A
10:25-10:45 – Advances of 2020-2021 in metastatic disease
Svetlana Kutukova, RU
10:45-10:50 – Q&A
Treatment intensification and de-escalation. Whom and when?
10:50-11:10 – Surgeon`s perspectives
Ilya Romanov, RU
11:10-11:30 – Radiotherapist`s perspectives
Pierre Blanchard, FR
11:30-11:50 – Medical oncologist’ perspectives
Amanda Psyrri, GR
11:50-12:10 – Q&A, panel discussion
12:10-13:10 – Clinical case discussion (3x20’)
Yuri Alymov, RU
Anastasia Ignatova, RU
David Safarow, RU
13:10-14:40 – Virtual Lunch Break
13:30-14:30 – Satellite Symposium MSD
SESSION 2. Colorectal carcinoma
Chairs:
Elizabeth Smyth, UK
Alexey Tryakin, RU
14:40-15:05 – Practice changing studies in rectal carcinoma. Is the total neoadjuvant therapy a new standard of care?
Mark Saunders, UK
15:05-15:10 – Q&A
15:10-15:30 – Practice changing studies in metastatic disease
Miriam Koopman, NL
15:30-15:35 – Q&A
15:35-16:00 – Rectal carcinoma with liver metastases. How to choose the correct route?
Elizabeth Smyth, UK
16:00-16:05 – Q&A
Third line of treatment. Is therapy reinduction a preferred option for the majority of patients?
16:05-16:20 – Pro
Alexey Tryakin, RU
16:20-16:35 – Contra
Ivan Rykov, RU
16:35-16:40 – Q&A
16:40-17:00 – Molecular driven treatment in later lines
Mikhail Fedyanin, RU
17:00-17:05 – Q&A
17:05-18:05 – Clinical case discussion (3x20’)
Elizaveta Poljanskaja, RU
Sergei Kuzin, RU
Michail Kramchaninov, RU
18:05-18:15 – Virtual Break
Hall 1
18:15-19:35 – Bristol Myers Squibb Satellite Symposium
Bristol Myers Squibb Satellite Symposium
18:15-18:20 – Intruduction
18:20-18:40 – Immunotherapy Potential in Esophageal Cancer
Alexey Tryakin, RU
18:40-19:10 – New Immune Combinations for Gastric and Esophageal-Gastric Junction Cancer
Mikhail Fedyanin, RU
19:10-19:35 – Panel Discussion
Hall 2
18:15-19:25 – Satellite Symposium AstraZeneca
AstraZeneca medical satellite symposia
Chairmen:
Ludmila Zhukova, RU
Elena Artamonova, RU
18:15-18:20 – Welcome remarks
18:20-18:45 – New hope for high risk patients with early BRCA-associated breast cancer
Ludmila Zhukova, RU
18:45-19:10 – Is a breakthrough possible in the therapy of pretreated patients with metastatic HER2-positive breast cancer?
Elena Artamonova, RU
19:10-19:20 – Q&A session
19:20-19:25 – Closing remarks
Note: Each 20-minute slot for clinical case discussion includes 15’ case presentation and 5’ Q&A/panel discussion.
Friday, June 11th 2021 (Central European Summer Time)
SESSION 3. Sarcoma and GIST
Chairs:
Alexander Fedenko, RU
Silvia Stacchiotti, IT
09:00-09:25 – Practice changing studies in sarcoma and GIST
Silvia Stacchiotti, IT
09:25-09:30 – Q&A
09:30-09:50 – Diagnostic pathology in soft tissue sarcoma. What clinicians have to know?
Paolo Dei Tos, IT
09:50-09:55 – Q&A
09:55-10:20 – Chemotherapy of localized and advanced soft tissue sarcoma. Is there a room for personalized treatment?
Robin Jones, UK
10:20-10:25 – Q&A
10:25-10:50 – Pediatric sarcoma in adults
Jean-Yves Blay, FR
10:50-10:55 – Q&A
10:55-11:20 – Treatment options of retroperitoneal sarcoma after the STRASS study results
Silvie Bonvalot, FR
11:20-11:25 – Q&A
11:25-12:25 – Clinical case discussion (3x20’)
Andrey Kulaga, RU
Anastasia Tararykova, RU
Vitalij Egorenkov, RU
12:35-13:35 – Virtual Lunch Break
Hall 1
12:35-13:35 – Satellite Symposium Roche
Satellite Symposium Roche
Chairman:
Anton Snegovoy, RU
12:35-12:55 – Search for new opportunities for the development of Personal Healthcare in Russia. Role of the data and evidence in real clinical practice
Ali Mudunov, RU
12:55-13:15 – Value of molecular genetic diagnostic methods in patients with tumors of undetected primary localization. Clinical decision support system (Peer-To-Peer, Molecular Tumor Board)
Anton Snegovoy, RU
13:15-13:35 – Experience of Complex Genomic Profiling application in clinical practice. Molecular target therapy of the head and neck tumors
Maxim Pak, RU
Hall 2
12:35-13:35 – Satellite Symposium Pfizer
Pfizer Satellite symposium
Chairman:
Vsevolod Matveev, RU
12:35-12:40 – Introduction
Vsevolod Matveev, RU
12:40-12:50 – RCC first line therapy: clinical guidelines discussion
Vsevolod Matveev, RU
12:50-13:10 – The role of IO-TKI combinations in first line therapy
Alexey Kalpinsky, RU
13:10-13:30 – AE management while treating with IO-TKI therapy
Maria Volkova, RU
13:30-13:35 – Q&A
SESSION 4. Breast carcinoma
Chairs:
Giuseppe Curigliano, IT
Timur Mitin, USA
Mona Frolova, RU
13:50-14:15 – Practice changing studies in early stages
Nadia Harbeck, DE
14:15-14:20 – Q&A
14:20-14:45 – Practice changing studies in metastatic disease
Giuseppe Curigliano, IT
14:45-14:50 – Q&A
Treatment intensification and de-escalation in nonmetastatic disease. Whom and when?
14:50-15:10 – Surgeon`s perspectives
Alexander Petrovsky, RU
15:10-15:30 – Radiotherapist`s perspectives
Timur Mitin, USA
15:30-15:50 – Medical oncologist’ perspectives
Mona Frolova, RU
15:50-16:10 – Q&A, panel discussion
16:10-17:10 – Clinical case discussion (3x20’)
Elena Glazkova, RU
Elena Tsareva, RU
Olga Gorbacheva, RU
17:10-17:20 – Adjourn and Closing Remarks
Note: Each 20-minute slot for clinical case discussion includes 15’ case presentation and 5’ Q&A/panel discussion.